Oxygen therapy for heart attack recovery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effects of supersaturated oxygen therapy on patients who have experienced an acute anterior ST-segment elevation myocardial infarction (STEMI) and have undergone primary percutaneous coronary intervention (PCI). Patients presenting within 6 hours of symptom onset will be enrolled and randomized to receive either the oxygen therapy or a sham treatment after their PCI procedure. The study will assess various outcomes, including blood samples, imaging scans, and health questionnaires, to evaluate the therapy's effectiveness in preventing heart failure and improving heart function. The trial aims to provide new insights into treatment options for heart attack recovery.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥18 years.
2. Ischemic time ≤6 hours from symptom onset
3. Acute anterior ST-segment elevation myocardial infarction
4. Infarct-related left anterior descending coronary artery TIMI flow grade 2-3 at the end of PCI
5. Radial artery access
6. Partial pressure of oxygen (PaO2) \>80 mmHg (10.7 kPa)

Exclusion Criteria:

1. Proximal coronary artery stenosis that restricts blood flow with the SSO2 catheter in place
2. Post-PCI non-stented dissection or perforation.
3. Moderate - severe heart valve stenosis, insufficiency, pericardial disease, or non-ischaemic cardiomyopathy
4. Known pregnancy.
5. Cardiogenic shock
6. Contra-indication to anticoagulation
7. Acute mechanical complication e.g., ventricular septal rupture, pseudoaneurysm, mitral regurgitation
8. Hemoglobin \<10 g/dL
9. Major bleeding or major surgery within the past two months
10. Contra-indication to cardiovascular magnetic resonance (CMR) imaging e.g., severe claustrophobia, metallic foreign body.
11. Lack of witness verbal consent.

Where it's running

• Golden Jubilee National Hospital
  Clydebank, Dunbartonshire, United Kingdom Recruiting

Study contacts

• Study coordinator: Colin Berry, BSc MBChB PhD
• Email: colin.berry@glasgow.ac.uk
• Phone: 441419515180

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Orticumab to reduce coronary artery inflammation after a heart attack

  This tests whether orticumab can reduce coronary artery inflammation over six months in people who had a heart attack and show high inflammation on coronary CT angiography.

  Recruiting at 39 sites Phase 2 Abcentra · Los Angeles, California and 40 other locations · NCT06927739

• Comparing early and late medication for heart attack recovery

  This study tests whether giving heart medications right away or waiting a bit helps people recover better after a heart attack.

  Recruiting Phase 4 Vastra Gotaland Region · Gothenburg · NCT06562582

• Using eplerenone to treat heart injury in patients with small vessel disease

  This study is testing if the medication eplerenone can help reduce heart damage and improve recovery for patients with heart injuries caused by small vessel disease.

  Recruiting at 2 sites Phase 2 NHS National Waiting Times Centre Board · East Kilbride, Lanarkshire and 1 other locations · NCT05198791

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.